Electromed, Inc. (ELMD)
| Market Cap | 213.01M |
| Revenue (ttm) | 68.86M |
| Net Income (ttm) | 8.99M |
| Shares Out | 8.28M |
| EPS (ttm) | 1.03 |
| PE Ratio | 24.99 |
| Forward PE | 21.45 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 16,771 |
| Open | 25.95 |
| Previous Close | 26.00 |
| Day's Range | 25.61 - 26.06 |
| 52-Week Range | 17.73 - 30.73 |
| Beta | 0.32 |
| Analysts | Strong Buy |
| Price Target | 36.00 (+39.86%) |
| Earnings Date | May 12, 2026 |
About ELMD
Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis, and post-surgical complications; SmartVest... [Read more]
Financial Performance
In fiscal year 2025, Electromed's revenue was $64.00 million, an increase of 16.97% compared to the previous year's $54.72 million. Earnings were $7.54 million, an increase of 46.35%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ELMD stock is "Strong Buy." The 12-month stock price target is $36.0, which is an increase of 39.86% from the latest price.
News
Electromed Transcript: The 38th Annual Roth Conference
A profitable, debt-free medical device company specializing in airway clearance is expanding its reach in a large, underserved market for bronchiectasis. Product innovation, strong payer coverage, and a high-touch patient model drive growth, with ongoing investments in sales force and shareholder returns.
Electromed Earnings Call Transcript: Q2 2026
Q2 saw record revenue and profit growth, led by strong home care and distributor channels, with gross margin rising to 78.4%. Strategic initiatives expanded market reach and payer coverage, while a $10 million stock repurchase program and no debt underscore financial strength.
Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Second Quarter
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Financial Performance in Fiscal 2026 Second Quarter.
Electromed, Inc. to Report Q2 Fiscal 2026 Financial Results on February 10, 2026
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its...
Electromed, Inc. to Participate in Noble Capital Markets' 21st Annual Emerging Growth Equity Conference
New Prague, Minnesota--(Newsfile Corp. - November 20, 2025) - Electromed, Inc. (NYSE American: ELMD) ("Electromed" or the "Company"), a leader in innovative airway clearance technologies, today announ...
Electromed Earnings Call Transcript: Q1 2026
Q1 saw 15% revenue growth to $16.9M, with strong gains across all channels and a 45% rise in net income. Strategic investments in sales, manufacturing, and digital tools drove operational efficiency, while a $10M buyback and robust cash position support future growth.
Electromed, Inc. Announces First Quarter Fiscal 2026 Results
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed Reports First Quarter Fiscal 2026 Results.
Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q1 Fiscal 2026 Financial Results on November 12, 2025.
Electromed, Inc. to Participate in LD Micro Main Event XIX
Management will present Monday, October 20, 2025 at 10:00 am PT New Prague, Minnesota--(Newsfile Corp. - October 13, 2025) - Electromed, Inc. (NYSE American: ELMD) ("Electromed" or the "Company"), a l...
Electromed, Inc. Announces Share Repurchase Authorization
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Share Repurchase Authorization.
Electromed Earnings Call Transcript: Q4 2025
Delivered record revenue and profit growth for the 11th consecutive quarter, with Q4 revenue up 17% year-over-year and strong gains across all segments. Fiscal 2025 saw robust margins, expanded sales productivity, and significant capital returned to shareholders.
Electromed, Inc. Announces Record Fiscal 2025 Fourth Quarter and Full Year Financial Results
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced financial results for the three months ...
Electromed, Inc. to Report Q4 Fiscal 2025 Financial Results on August 26, 2025
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its...
Electromed Transcript: Canaccord Genuity’s 45th Annual Growth Conference
SmartVest addresses a large, underpenetrated and growing market for bronchiectasis and COPD overlap, with strong clinical outcomes and a direct-to-patient model driving high margins. Operational improvements and payer coverage support double-digit growth and profitability.
Electromed, Inc. to Participate in the Canaccord Genuity 45th Annual Growth Conference
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed to Participate in Canaccord Genuity 45th Annual Growth Conference.
Electromed Transcript: Q2 Virtual Investor Summit Event
A leading airway clearance company highlighted strong revenue growth, high gross margins, and a unique direct-to-patient model. The firm targets a large, underdiagnosed market with best-in-class technology, driving patient outcomes and expanding through sales force and payer initiatives.
Electromed, Inc. to Present at the Investor Summit Virtual on June 10, 2025
NEW PRAGUE, MN / ACCESS Newswire / June 9, 2025 / Electromed, Inc. announced that Jim Cunniff, President and Chief Executive Officer, will be presenting at the Investor Summit Virtual taking place on ...
Electromed, Inc. to Join Russell 2000® and Russell 3000® Indexes
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that the Company will ...
Electromed Earnings Call Transcript: Q3 2025
Delivered double-digit revenue and net income growth for the 10th straight quarter, driven by strong home care sales, expanded marketing, and operational improvements. Maintained high gross margins and robust cash position while executing share repurchases.
Electromed, Inc. Announces Fiscal 2025 Third Quarter Results
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Fiscal 2025 Third Quarter Results.
Electromed, Inc. Schedules its Third Quarter Fiscal 2025 Financial Results Conference Call for May 13, 2025 at 5:00 p.m. ET
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. (“Electromed” or the “Company”) (NYSE American: ELMD), a leader in innovative airway clearance technologies, today announced that it will issue its...
Electromed Transcript: 15th Annual LD Micro Invitational 2025
A leading airway clearance device provider is expanding in a large, underdiagnosed market, focusing on bronchiectasis with innovative, patient-friendly products. Strong financials, direct billing, and targeted growth strategies support double-digit organic growth.
Electromed, Inc. to Present at the LD Micro Invitational XV
New Prague, Minnesota--(Newsfile Corp. - April 3, 2025) - Electromed, Inc. (NYSE American: ELMD) announced today that it will be participating in the 15th Annual LD Micro Invitational at the Westin Gr...
Electromed Transcript: Sidoti Small-Cap Virtual Conference
A leading respiratory care company is expanding in the underpenetrated bronchiectasis market, leveraging innovative products, direct-to-patient models, and robust clinical evidence. Strong financials, ongoing sales force expansion, and active portfolio management support continued growth.
Electromed Transcript: Oppenheimer 35th Annual Health Care MedTech and Services Conference
The company leverages a direct-to-patient model and innovative airway clearance technology to address a large, underdiagnosed market, driving double-digit growth and strong margins. Strategic investments in payer coverage, digital presence, and patient support underpin continued expansion.